Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors

NCT03866525 is registered in ClinicalTrials.gov with Binhui Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03866525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03866525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors
Lead sponsor
Binhui Biopharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 2, 2019
Completion date
August 30, 2025
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancer, solid tumor